大麻使用障碍的全基因组关联研究荟萃分析
该研究整合精神病学基因组学联盟物质使用障碍工作组、iPSYCH和deCODE样本(20 916例病例、363 116例对照),对大麻使用障碍进行全基因组关联研究荟萃分析,鉴定出两个全基因组显著位点,并发现大麻使用障碍与大麻使用遗传相关但遗传基础不完全相同,且与其他精神病理存在正向遗传相关。
要点
- 鉴定出染色体7(FOXP2)和染色体8(CHRNA2/EPHX2附近)两个全基因组显著位点。
- 大麻使用障碍与大麻使用遗传相关(rg 0·50),但与22项特质中12项的遗传相关显著不同。
- 大麻使用障碍与ADHD、重性抑郁和精神分裂症存在正向遗传相关。
核心结论
- 大麻使用障碍与其他精神病理存在共享遗传易感性,且大麻使用与大麻使用障碍的遗传易感性存在区别。
研究设计与样本
- 采用精神病学基因组学联盟物质使用障碍工作组、iPSYCH和deCODE样本进行全基因组关联研究荟萃分析,共20 916例病例和363 116例对照,并用连锁不平衡得分回归计算遗传相关。
主要发现
- 染色体7新位点FOXP2(lead SNP rs7783012;OR 1·11,95% CI 1·07-1·15,p=1·84 × 10-9)达全基因组显著。
- 染色体8位点(near CHRNA2和EPHX2,lead SNP rs4732724;OR 0·89,95% CI 0·86-0·93,p=6·46 × 10-9)达全基因组显著。
- 大麻使用障碍与大麻使用遗传相关(rg 0·50,p=1·50 × 10-21),但与22项特质中12项的遗传相关显著不同。
- 大麻使用障碍与ADHD、重性抑郁和精神分裂症呈正向遗传相关。
关键数值与推荐
- 全基因组显著位点:染色体7 FOXP2(rs7783012,OR 1·11,95% CI 1·07-1·15,p=1·84 × 10-9)。
- 全基因组显著位点:染色体8 near CHRNA2和EPHX2(rs4732724,OR 0·89,95% CI 0·86-0·93,p=6·46 × 10-9)。
- 大麻使用障碍与大麻使用遗传相关rg 0·50(p=1·50 × 10-21)。
临床怎么用
- 提示临床关注大麻使用障碍与其他精神障碍的共享遗传风险,评估时注意共病精神病理。
- 支持将大麻使用与大麻使用障碍作为部分不同的遗传实体进行区分评估。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variation in liability to cannabis use disorder has a strong genetic component (estimated twin and family heritability about 50-70%) and is associated with negative outcomes, including increased risk of psychopathology. The aim of the study was to conduct a large genome-wide association study (GWAS) to identify novel genetic variants associated with cannabis use disorder. METHODS: To conduct this GWAS meta-analysis of cannabis use disorder and identify associations with genetic loci, we used samples from the Psychiatric Genomics Consortium Substance Use Disorders working group, iPSYCH, and deCODE (20 916 case samples, 363 116 control samples in total), contrasting cannabis use disorder cases with controls. To examine the genetic overlap between cannabis use disorder and 22 traits of interest (chosen because of previously published phenotypic correlations [eg, psychiatric disorders] or hypothesised associations [eg, chronotype] with cannabis use disorder), we used linkage disequilibrium score regression to calculate genetic correlations. FINDINGS: We identified two genome-wide significant loci: a novel chromosome 7 locus (FOXP2, lead single-nucleotide polymorphism [SNP] rs7783012; odds ratio [OR] 1·11, 95% CI 1·07-1·15, p=1·84 × 10-9) and the previously identified chromosome 8 locus (near CHRNA2 and EPHX2, lead SNP rs4732724; OR 0·89, 95% CI 0·86-0·93, p=6·46 × 10-9). Cannabis use disorder and cannabis use were genetically correlated (rg 0·50, p=1·50 × 10-21), but they showed significantly different genetic correlations with 12 of the 22 traits we tested, suggesting at least partially different genetic underpinnings of cannabis use and cannabis use disorder. Cannabis use disorder was positively genetically correlated with other psychopathology, including ADHD, major depression, and schizophrenia. INTERPRETATION: These findings support the theory that cannabis use disorder has shared genetic liability with other psychopathology, and there is a distinction between genetic liability to cannabis use and cannabis use disorder. FUNDING: National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing; The European Commission, Horizon 2020; National Institute of Child Health and Human Development; Health Research Council of New Zealand; National Institute on Aging; Wellcome Trust Case Control Consortium; UK Research and Innovation Medical Research Council (UKRI MRC); The Brain & Behavior Research Foundation; National Institute on Deafness and Other Communication Disorders; Substance Abuse and Mental Health Services Administration (SAMHSA); National Institute of Biomedical Imaging and Bioengineering; National Health and Medical Research Council (NHMRC) Australia; Tobacco-Related Disease Research Program of the University of California; Families for Borderline Personality Disorder Research (Beth and Rob Elliott) 2018 NARSAD Young Investigator Grant; The National Child Health Research Foundation (Cure Kids); The Canterbury Medical Research Foundation; The New Zealand Lottery Grants Board; The University of Otago; The Carney Centre for Pharmacogenomics; The James Hume Bequest Fund; National Institutes of Health: Genes, Environment and Health Initiative; National Institutes of Health; National Cancer Institute; The William T Grant Foundation; Australian Research Council; The Virginia Tobacco Settlement Foundation; The VISN 1 and VISN 4 Mental Illness Research, Education, and Clinical Centers of the US Department of Veterans Affairs; The 5th Framework Programme (FP-5) GenomEUtwin Project; The Lundbeck Foundation; NIH-funded Shared Instrumentation Grant S10RR025141; Clinical Translational Sciences Award grants; National Institute of Neurological Disorders and Stroke; National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences.
引用
- Johnson EC, Demontis D, Thorgeirsson TE, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020. PMID: 33096046. doi:10.1016/S2215-0366(20)30339-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。